MX2023014769A - Metodo y composiciones para la reprogramacion neuronal. - Google Patents
Metodo y composiciones para la reprogramacion neuronal.Info
- Publication number
- MX2023014769A MX2023014769A MX2023014769A MX2023014769A MX2023014769A MX 2023014769 A MX2023014769 A MX 2023014769A MX 2023014769 A MX2023014769 A MX 2023014769A MX 2023014769 A MX2023014769 A MX 2023014769A MX 2023014769 A MX2023014769 A MX 2023014769A
- Authority
- MX
- Mexico
- Prior art keywords
- transcription factor
- mutant
- bhlh
- encoding
- serineâ
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208627P | 2021-06-09 | 2021-06-09 | |
| PCT/CA2022/050923 WO2022256933A1 (en) | 2021-06-09 | 2022-06-09 | Method and compositions for neuronal reprogramming |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014769A true MX2023014769A (es) | 2024-01-30 |
Family
ID=84424544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014769A MX2023014769A (es) | 2021-06-09 | 2022-06-09 | Metodo y composiciones para la reprogramacion neuronal. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250282837A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4352085A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024521401A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240032021A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117881692A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022288230A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023025888A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3222129A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL309190A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023014769A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022256933A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021078588A1 (en) * | 2019-10-21 | 2021-04-29 | École Polytechnique Fédérale De Lausanne (Epfl) | Synthesis of branching morphologies |
| CN115670390B (zh) * | 2022-12-30 | 2023-04-07 | 广东工业大学 | 一种帕金森病轴向症状严重程度表征方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014037527A1 (en) * | 2012-09-07 | 2014-03-13 | Cambridge Enterprise Limited | Maturation of mammalian cells by modulation of protein phosphorylation |
-
2022
- 2022-06-09 EP EP22819038.5A patent/EP4352085A4/en active Pending
- 2022-06-09 MX MX2023014769A patent/MX2023014769A/es unknown
- 2022-06-09 KR KR1020247000754A patent/KR20240032021A/ko active Pending
- 2022-06-09 US US18/568,747 patent/US20250282837A1/en active Pending
- 2022-06-09 AU AU2022288230A patent/AU2022288230A1/en active Pending
- 2022-06-09 CN CN202280051836.7A patent/CN117881692A/zh active Pending
- 2022-06-09 IL IL309190A patent/IL309190A/en unknown
- 2022-06-09 BR BR112023025888A patent/BR112023025888A2/pt not_active Application Discontinuation
- 2022-06-09 WO PCT/CA2022/050923 patent/WO2022256933A1/en not_active Ceased
- 2022-06-09 CA CA3222129A patent/CA3222129A1/en active Pending
- 2022-06-09 JP JP2023575711A patent/JP2024521401A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250282837A1 (en) | 2025-09-11 |
| EP4352085A4 (en) | 2025-07-23 |
| CA3222129A1 (en) | 2022-12-15 |
| JP2024521401A (ja) | 2024-05-31 |
| EP4352085A1 (en) | 2024-04-17 |
| BR112023025888A2 (pt) | 2024-02-27 |
| KR20240032021A (ko) | 2024-03-08 |
| AU2022288230A1 (en) | 2023-12-21 |
| WO2022256933A1 (en) | 2022-12-15 |
| IL309190A (en) | 2024-02-01 |
| CN117881692A (zh) | 2024-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021071788A3 (en) | Oligonucleotide compositions and methods of use thereof | |
| WO2020227691A3 (en) | Oligonucleotide compositions and methods of use thereof | |
| ZA202408862B (en) | Compositions and methods for neurological diseases | |
| WO2021016112A3 (en) | Non-sedating dexmedetomidine treatment regimens | |
| PH12021551632A1 (en) | Imidazo[1,2-b]pyridazine il-17a inhibitors | |
| EP4599847A3 (en) | Prefusion coronavirus spike proteins and their use | |
| WO2018049152A8 (en) | Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
| SG11201810769QA (en) | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases | |
| EP4269596A3 (en) | Engineered meganucleases specific for recognition sequences in the pcsk9 gene | |
| PH12018502604A1 (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| NZ765495A (en) | 1, 3, 4, 5-tetrahydro-2h-pyrido[4,3-b]indole derivatives for the treatment, alleviation or prevention of disorders associated with tau aggregates like alzheimer’s disease | |
| IS2923B (is) | Aðferðir til að meðhöndla eða fyrirbyggja með 2,4-pýrimidíndíamínefnasamböndum sjálfsónæmissjúkdóma | |
| MX2022006573A (es) | Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias. | |
| WO2019075456A3 (en) | Methods and substances for prevention and treatment of neurodegenerative diseases | |
| MX2020013115A (es) | Compuestos de tetrahidrobenzofuro[2,3-c]piridina y beta-carbolina para el tratamiento, el alivio o la prevencion de trastornos asociados con los agregados de tau. | |
| MY194722A (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors | |
| BR112022021964A2 (pt) | Ácidos nucleicos modificados que codificam aspartoacilase (aspa) e vetores para terapia gênica | |
| IL311208A (en) | 2-amino-5,5-dimethylhexanoic acid derivatives as sortilin modulators for use in the treatment of disease of the central nervous system | |
| WO2020186155A3 (en) | Synthetic neuromodulatory peptides | |
| EP4327884A3 (en) | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as lrrk2, nuak1 and/or tyk2 kinase modulators for the treatment of e.g. autoimmune diseases | |
| BR112023025888A2 (pt) | Método e composições para reprogramação neuronal | |
| WO2021093134A9 (zh) | 一组蛇神经生长因子及蛇神经生长因子前体在治疗老年痴呆上的应用 | |
| Chi et al. | Distinct neurological disorders with C9orf72 mutations: genetics, pathogenesis, and therapy | |
| WO2023212521A3 (en) | Treatments of disorders of myelin | |
| EP4461362A3 (en) | Nk1-antagonist combination and method for treating synucleinopathies |